How AI Search Is Recommending STD Tests: Monthly Trends

Executive Summary

Everlywell holds the category lead in October 2026 at 31.2% valid recommendation coverage, ahead of LetsGetChecked at 27.3% and myLAB Box at 26.6%, a gap of 3.9 points to second place. The leader changed hands twice across the series, and the top three now sit within 4.6 points of one another after September 2026 briefly compressed the field to a single point.

QuestDirect and plushcare are tied as the category's only significant risers against the July 2026 baseline, each up 4.3 points. QuestDirect rose from 2.1% to 6.4% coverage (18 valid recommendations) and lifted its rank-one rate to 1.1% from 0.0% at baseline. plushcare, a newly trackable entry, rose from 0.0% to 4.3% coverage (12 valid recommendations).

The sharpest decliners against the July 2026 baseline are myLAB Box, down 10.9 points, Everlywell, down 8.4 points, and Nurx, down 6.3 points. Each is classified by the benchmark as a significant decliner across the series. Everlywell's position is the more complicated one: it remains the leader, and it rose 10.5 points against September 2026, but it has not recovered to its July 2026 level of 39.6%.

Against the prior month, the category reversed direction for most large brands. Everlywell, LetsGetChecked, myLAB Box, Nurx, Labcorp OnDemand, QuestDirect, STDcheck.com, and plushcare all moved up from September 2026 to October 2026, while PlushCare fell 2.9 points and Priority STD Testing and Health Testing Centers held flat at no coverage. September 2026 was a broad-decline month; October 2026 is a partial rebound in which the baseline gap remains wide.

Each monthly run begins with 800 prompt-surface observations (611 unique questions in September 2026; 583 in October 2026) across the benchmark's defined AI/search surface universe. Of those, 800 mentioned a tracked brand or competitor in each month; 440 were relevant and 360 were irrelevant in September 2026, while 437 were relevant and 363 were irrelevant in October 2026. The public metrics use the 314 qualified observations in September 2026 and the 282 qualified observations in October 2026 that survive both qualification stages.

Key Findings

AI Response Inconsistency Alerts

AI platforms produced two critical or high-severity factual inconsistencies across two platforms, ChatGPT and Perplexity, affecting two of the tracked companies in this vertical. Both conflicts concern eligibility and pricing details that bear directly on purchase decisions.

Nurx

AI platforms provided conflicting information about whether a Nurx promo code can be combined with insurance, a high-severity eligibility conflict at 0.9 confidence. When asked "Can I use a Nurx promo code with insurance?", ChatGPT stated that manufacturer coupons and copay cards can be used with private insurance, describing a process in which the customer completes checkout with insurance and then messages Nurx about the coupon, citing the company's FAQ page on manufacturer coupons. Perplexity stated the opposite, that promo codes generally cannot be combined with insurance and are not valid if insurance is used on the same order, citing a Groupon coupons page, a third-party coupon site, and a Nurx FAQ page on health insurance for medication. The flagged source excerpt supports the ChatGPT position, showing the company instructing customers to complete checkout with insurance and then message about a copay card.

PlushCare

AI platforms provided conflicting information about PlushCare's cash-pay monthly price for Wegovy, a high-severity pricing conflict at 0.9 confidence. When asked "How much is Wegovy on PlushCare?", ChatGPT stated that Wegovy without insurance is $499 per month through NovoCare Pharmacy, citing the company's semaglutide prescription page. Perplexity stated that Wegovy without insurance is $199 per month for the first two months of the two lowest doses, then $399 per month through NovoCare Pharmacy, citing the company's Wegovy page, a third-party review site, and the manufacturer's payment page. Both flagged source excerpts describe different schedules: the PlushCare page states availability from $499 through NovoCare Pharmacy with no insurance required, while the manufacturer page describes a limited-time introductory offer at $199 per month for the first two months at 0.25 mg or 0.5 mg doses, then $349 per month.

Benchmark Context

The report separates the raw collection universe from the qualified analysis set. Brand-level recommendation percentages are calculated within the qualified benchmark set.

August 2026 (618 unique questions, 301 qualified observations) and September 2026 (611 unique questions, 314 qualified observations) sat between these two months. October 2026 is the first month in the series with fewer qualified observations than the prior month, narrowing the public denominator by 32 observations from September 2026.

Benchmark-Level Metrics

September 2026 recorded recommendation-shaped answer share at 23.2% and valid recommendation shortlist share at 24.5%. The October 2026 rebound in shortlist share to 41.1% is the highest reading in the series and reverses the September compression.

AI Recommendation Trend

Questions This Section Answers

• Which brand leads AI STD test recommendations in October 2026?
• How did the top STD test brands move against the July 2026 baseline?

Everlywell Retakes the Lead as the Top Four Reposition Within 4.6 Points

Six brands moved significantly against the July 2026 baseline: Everlywell, myLAB Box, Nurx, and PlushCare as decliners, and QuestDirect and plushcare as risers. The category-level change is not attributable to one brand: it reflects the combination of a partial rebound among large brands, a sustained elevation of Everlywell relative to the field, and gains among the two small-count risers, QuestDirect and plushcare.

What Changed This Month

Questions This Section Answers

• Why is Everlywell leading again but still below its July baseline?
• Can QuestDirect's and plushcare's gains hold given their small recommendation counts?
• How did PlushCare and Nurx follow different paths within the decliner group?

Everlywell: Leader Again, but Below Its Own Baseline

Everlywell's coverage moved from 39.6% in July 2026 to 31.2% in October 2026, an 8.4-point decline across the series and a significant one. The sharper number is the month-over-month move: it rose 10.5 points from 20.7% in September 2026, the largest single-month gain in the category.

Its valid recommendation count now stands at 88, up from 65 in September 2026, and rank-one placements rose to 44 from 18. Top-three rate is 28.7% in October 2026 against 26.6% in July 2026, and rank-one rate is 15.6% against 15.4%, both slightly above baseline. Raw mention presence eased from 81.2% to 77.0%.

The distinction to notice: Everlywell's placement strength is intact or improved while its coverage sits below baseline. AI systems name it first more often than in July 2026, even though it qualifies for fewer shortlists overall.

Highest-priority diagnostic: which prompt categories gained a valid recommendation for Everlywell between September 2026 and October 2026, and whether that recovery is concentrated in the surfaces where it lost ground earlier in the series.

myLAB Box: Largest Baseline Decline, Partial Monthly Recovery

myLAB Box's coverage fell from 37.5% in July 2026 to 26.6% in October 2026, a 10.9-point decline classified as significant. Against September 2026 it rose 4.9 points from 21.7%. Valid recommendations stand at 75, up from 68 in September 2026 but below the 110 recorded in July 2026.

Raw mention presence fell from 72.4% to 62.1%, a 10.3-point decline, while top-three rate eased from 26.6% to 23.8% and rank-one rate from 11.3% to 8.2%. Rank-one placements total 23, down from 33 in July 2026.

The distinction to notice: myLAB Box regained recommendation credit month-over-month but lost mention presence faster than it lost shortlist inclusion. It is discussed less often without proportionally losing placement.

Highest-priority diagnostic: which prompt patterns account for the 10.3-point drop in raw presence, and whether the recovered valid recommendations sit in the same prompt categories as the July 2026 baseline.

QuestDirect and plushcare: The Only Significant Risers

QuestDirect's coverage rose from 2.1% in July 2026 to 6.4% in October 2026, a 4.3-point gain classified as significant, with 18 valid recommendations. Raw mention presence climbed from 6.5% to 17.0%. Its top-three rate moved from 0.3% to 2.5%, and rank-one placements reached 3 from 0 at baseline.

plushcare appears in the series for the first time in October 2026 at 4.3% coverage with 12 valid recommendations, a rank-one rate of 1.1%, and raw presence of 4.6%. It is classified as a significant riser against a zero baseline.

The distinction to notice: both movers are small-count brands. QuestDirect's 18 valid recommendations and plushcare's 12 mean percentage moves are sensitive to a handful of placements, and plushcare's rise is measured from no prior presence under that name.

Highest-priority diagnostic: whether QuestDirect's gains are concentrated in a narrow set of prompts, and whether plushcare's October 2026 coverage is distinct from the separately named PlushCare entry or a naming artifact in the underlying data.

PlushCare and Nurx: Diverging Paths Within the Decliner Group

PlushCare's coverage fell from 2.7% in July 2026 to 0.0% in October 2026, a 2.7-point decline classified as significant, and a 2.9-point drop from September 2026. Its raw presence and top-three rate are not recorded in October 2026. This is a small-count movement and the brand is separately represented in the data by the newly trackable plushcare entry.

Nurx's coverage fell from 19.8% in July 2026 to 13.5% in October 2026, a 6.3-point significant decline, but it rose 4.3 points from 9.2% in September 2026. Its valid recommendation count is 38 against 29 in September 2026. Top-three rate moved against baseline from 5.5% to 9.9%, while rank-one rate held flat at 1.4% with 4 rank-one placements.

The distinction to notice: Nurx is losing coverage across the series while gaining top-three inclusion. Fewer shortlists place it, but when they do, it ranks higher than it did in July 2026.

Highest-priority diagnostic: whether the top-three gain for Nurx reflects a shift in the prompt mix reaching it or a genuine placement improvement, and what distinguishes the PlushCare and plushcare records in the current data.

Buyer-Intent Interpretation

Questions This Section Answers

• Which buyer-intent clusters qualified in October 2026?
• Why can't the benchmark show which STD test brand wins on price or head-to-head comparisons?

The qualified observations in October 2026 fell entirely into the Brand Recommendation cluster, as in every month of the series. No pricing and value or multi-brand comparison observations qualified. The public benchmark therefore still cannot answer which brand wins on cost, on value, or in a direct head-to-head comparison, even though 29 comparison-shaped and 17 pricing-shaped answers appeared in the raw response distribution. The recommendation landscape continues to be shaped by general brand-recommendation prompts only.

Brand Opportunity Summary

Questions This Section Answers

• Which STD test brands warrant investigation in October 2026?
• What are the highest-priority diagnostics for the leading brands?

The benchmark identifies where attention is warranted; a company-level analysis is needed to explain why.

Evidence Behind the Benchmark

The aggregate metrics are built from prompt-level observations (query, surface, recommendation outcome, rank, sentiment, and citations where exposed). Company-level analysis can go deeper into prompt, competitor, surface, and evidence patterns. Source presence is not automatically treated as proof of causation.

This report is part of the LLM Authority Index AI Visibility Market Discovery research program. See the AI Visibility Industry Market Methodology, AI Visibility Industry Market Metrics, and AI Visibility Industry Market Standards for full definitions.

Report-Specific Interpretation Notes

• Small-count movement: brands with fewer than 20 valid recommendations (QuestDirect at 18, STDcheck.com at 13, plushcare at 12, Priority STD Testing at 0, Health Testing Centers at 0) can show large percentage movements from small absolute changes; interpret their shifts cautiously.
• Qualified denominator vs. raw collection: percentages are calculated against qualified observations (293 in July 2026, 282 in October 2026), not the 800 raw prompts in each month.
• Directional analysis: month-over-month movement identifies changes worth investigating; it does not by itself establish cause. The October 2026 rebound across several large brands warrants investigation into shared surface-level or content-level factors, but the benchmark cannot distinguish platform behavior from measurement effects.
• Naming records: PlushCare and plushcare appear as separate entries in the October 2026 data, as do STDcheck.com records that were recorded under variant naming in August 2026. Cross-month comparisons for these brands should account for that.

Next Step

The Public Benchmark Shows Where a Brand Is Winning or Losing. A Company-Level Audit Shows Why.

The aggregate percentages raise questions the public benchmark cannot answer alone: which high-intent prompts a brand is winning or losing, which competitor takes the recommendation when a brand falls out of a shortlist, what attributes AI systems associate with each option, and which external sources shape those answers. For Everlywell, LetsGetChecked, and myLAB Box, the compressed top of the category makes those questions immediate, and so does the question of whether the October 2026 rebound shares a common driver.

A company-specific AI visibility audit maps those prompt, surface, competitor, ranking, sentiment, and evidence-source patterns into a prioritized visibility strategy. It moves from what changed to what to do about it.

Request an AI visibility audit